Require insurance coverage for pre-exposure prophylaxis medication
Summary
LB715 would require most individual and group sickness and accident insurance policies, hospital and medical expense policies, and self-funded employee benefit plans to cover pre-exposure prophylaxis (PrEP) medication when prescribed by a physician or other legally authorized health care professional. The bill specifically targets medication used to prevent human immunodeficiency virus (HIV) infection, and it applies unless federal law preempts the requirement or the policy is a specified disease or other limited-benefit policy.
The measure also states that insurers and plans may still apply ordinary deductible, copayment, and network incentive provisions contained in the policy or plan. In practical terms, LB715 would have added PrEP coverage to Nebraska insurance law and expanded access to HIV prevention medication by making coverage mandatory across a broad range of health plans.
Impact
LB715 would have amended Nebraska insurance requirements by mandating coverage for PrEP medication in most health insurance policies and self-funded employee benefit plans, subject to federal preemption and certain policy exceptions. It would have affected insurers, health plans, employers offering self-funded coverage, and insured individuals seeking HIV prevention treatment, while preserving existing cost-sharing and network rules.
Sentiment
The available record shows no committee transcript or vote detail, so there is no documented debate or recorded floor sentiment to assess. Based on the bill’s subject and its introduction as a coverage mandate for HIV prevention medication, the measure appears to have been framed as a public health and access-to-care proposal rather than a broad insurance overhaul. Its final status of indefinitely postponed indicates it did not advance to enactment.
Contention
The main likely point of contention is the requirement that insurers and self-funded plans cover PrEP medication, which could raise concerns about premium impacts, mandated-benefit expansion, and employer plan costs. Supporters would likely emphasize HIV prevention, public health benefits, and improved access to preventive medication, while opponents or cautious stakeholders would focus on cost, coverage mandates, and the extent to which state law should require benefits in private insurance and self-funded plans. The bill’s exception for federal preemption also suggests possible legal complexity around self-funded plans governed by ERISA.